Summary
This company is focused on developing innovative cell therapies aimed at treating cancer and autoimmune diseases. Utilizing advanced technologies, including D-Domain technology and the ddCAR and ARC-SparX platforms, the company is reimagining how cell therapy can be applied to enhance treatment efficacy. Their pipeline includes various clinical trials targeting multiple myeloma and other conditions, emphasizing a patient-centric approach and collaboration within the healthcare community.
Based on content on arcellx.com
kronosbio.com
San Mateo, CA
Biotechnology focused on cancer and autoimmune disease therapeutics.
We offer API access to our data.
8 of 8 checks passed
Label
Value
Active Dates
8.6 years — Since May 2016
Web Hosting
Platform
E-Mail Provider
Mimecast
NAICS Code
621511
SIC 4 Digit Code
2834
SIC 2 Digit Code
28
Industry
1. Biotechnology and Pharmaceuticals
2. Medical Laboratories
Vendor
Source
Microsoft
TXT Record
Adobe identity provider
TXT Record
Apple
TXT Record
CloudHealth
TXT Record
DocuSign
TXT Record
TXT Record
OneTrust
TXT Record
Smartsheet
TXT Record
Mimecast
TXT Record
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2017 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2019 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 |
|
|
|
|
|
|
|
|
|
|
|
|